UNCY
Market read
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
Invalidation: The isolated read changes if UNCY's group or a disclosed connection begins moving with it.
Research brief
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
No qualifying supportive evidence was identified.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“Cash used in operating activities was primarily due to the use of funds for development costs associated with our drug candidates, labor costs, consulting services, and other corporate expenditures for investor relations, compliance, and legal services.”10-Q · May 12, 2026 ↗
“Cash used in operating activities was primarily due to the use of funds for development costs associated with our drug candidates, labor costs, consulting services, and other corporate expenditures for investor relations, compliance, and legal services.”10-Q · May 12, 2026 ↗
“Cash used in operating activities was primarily due to the use of funds for development costs associated with our drug candidates, labor costs, consulting services, and other corporate expenditures for investor relations, compliance, and legal services.”10-Q · May 12, 2026 ↗
“This increase was primarily driven by a $2.4 million rise in marketing expenses associated with the commercial launch, $3.5 million in higher consulting and professional service costs, and $1.8 million in labor and related expenses.”10-K · Mar 30, 2026 ↗
Valuation discipline
Price/sales 193.2× · EV/sales 193.2×. Comparisons use only industry-matched filing peers.
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for UNCY. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
Jodie has not yet found a suitable current-versus-prior filing comparison for UNCY. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“Our future success depends on our ability to demonstrate and maintain a competitive advantage with respect to the development and commercialization of oxylanthanum carbonate, and any other product or product candidate, including those that may be in-licensed…”
“Our future success depends on our ability to demonstrate and maintain a competitive advantage with respect to the development and commercialization of oxylanthanum carbonate, and any other product or product candidate, including those that may be in-licensed…”
“Our future success depends on our ability to demonstrate and maintain a competitive advantage with respect to the development and commercialization of oxylanthanum carbonate, and any other product or product candidate, including those that may be in-licensed…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
UNCY is currently a Leader in the organic co-movement group Kidney Disease Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for UNCY; it is not active in the latest market snapshot.
Context history
No durable theme membership has been observed for this name yet.